Reviews Human Papillomavirus Bivalent Vaccine


No reviews yet.

Cervarix Drug Description
CERVARIX
[Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension
for Intramuscular Injection
DRUG DESCRIPTION
CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant]
is a non-infectious recombinant, AS04-adjuvanted vaccine that contains recombinant
L1 protein, the major antigenic protein of the capsid, of oncogenic HPV types
16 and 18. The L1 proteins are produced in separate bioreactors using the recombinant
Baculovirus expression vector system in a serum-free culture media composed
of chemically-defined lipids, vitamins, amino acids, and mineral salts. Following
replication of the L1 encoding recombinant Baculovirus in Trichoplusia ni
insect cells, the L1 protein accumulates in the cytoplasm of the cells. The
L1 proteins are released by cell disruption and purified by a series of chromatographic
and filtration methods. Assembly of the L1 proteins into virus-like particles
(VLPs) occurs at the end of the purification process. The purified, non-infectious
VLPs are then adsorbed on to aluminum (as hydroxide salt). The adjuvant system,
AS04, is composed of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) adsorbed
on to aluminum (as hydroxide salt).
CERVARIX is prepared by combining the adsorbed VLPs of each HPV type together with the AS04 adjuvant system in sodium chloride, sodium dihydrogen phosphate dihydrate, and Water for Injection.
CERVARIX is a sterile suspension for intramuscular injection. Each 0.5-mL dose
is formulated to contain 20 mcg of HPV type 16 L1 protein, 20 mcg of HPV type
18 L1 protein, 50 mcg of the 3-O-desacyl-4'-monophosphoryl lipid A (MPL),
and 0.5 mg of aluminum hydroxide. Each dose also contains 4.4 mg of sodium chloride
and 0.624 mg of sodium dihydrogen phosphate dihydrate. Each dose may also contain
residual amounts of insect cell and viral protein ( < 40 ng) and bacterial
cell protein ( < 150 ng) from the manufacturing process. CERVARIX does not
contain a preservative.
Last reviewed on RxList: 10/30/2009




Cervarix Drug Description
CERVARIX
[Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension
for Intramuscular Injection
DRUG DESCRIPTION
CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant]
is a non-infectious recombinant, AS04-adjuvanted vaccine that contains recombinant
L1 protein, the major antigenic protein of the capsid, of oncogenic HPV types
16 and 18. The L1 proteins are produced in separate bioreactors using the recombinant
Baculovirus expression vector system in a serum-free culture media composed
of chemically-defined lipids, vitamins, amino acids, and mineral salts. Following
replication of the L1 encoding recombinant Baculovirus in Trichoplusia ni
insect cells, the L1 protein accumulates in the cytoplasm of the cells. The
L1 proteins are released by cell disruption and purified by a series of chromatographic
and filtration methods. Assembly of the L1 proteins into virus-like particles
(VLPs) occurs at the end of the purification process. The purified, non-infectious
VLPs are then adsorbed on to aluminum (as hydroxide salt). The adjuvant system,
AS04, is composed of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) adsorbed
on to aluminum (as hydroxide salt).
CERVARIX is prepared by combining the adsorbed VLPs of each HPV type together with the AS04 adjuvant system in sodium chloride, sodium dihydrogen phosphate dihydrate, and Water for Injection.
CERVARIX is a sterile suspension for intramuscular injection. Each 0.5-mL dose
is formulated to contain 20 mcg of HPV type 16 L1 protein, 20 mcg of HPV type
18 L1 protein, 50 mcg of the 3-O-desacyl-4'-monophosphoryl lipid A (MPL),
and 0.5 mg of aluminum hydroxide. Each dose also contains 4.4 mg of sodium chloride
and 0.624 mg of sodium dihydrogen phosphate dihydrate. Each dose may also contain
residual amounts of insect cell and viral protein ( < 40 ng) and bacterial
cell protein ( < 150 ng) from the manufacturing process. CERVARIX does not
contain a preservative.
Last reviewed on RxList: 10/30/2009




Cervarix Drug Description
CERVARIX
[Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension
for Intramuscular Injection
DRUG DESCRIPTION
CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant]
is a non-infectious recombinant, AS04-adjuvanted vaccine that contains recombinant
L1 protein, the major antigenic protein of the capsid, of oncogenic HPV types
16 and 18. The L1 proteins are produced in separate bioreactors using the recombinant
Baculovirus expression vector system in a serum-free culture media composed
of chemically-defined lipids, vitamins, amino acids, and mineral salts. Following
replication of the L1 encoding recombinant Baculovirus in Trichoplusia ni
insect cells, the L1 protein accumulates in the cytoplasm of the cells. The
L1 proteins are released by cell disruption and purified by a series of chromatographic
and filtration methods. Assembly of the L1 proteins into virus-like particles
(VLPs) occurs at the end of the purification process. The purified, non-infectious
VLPs are then adsorbed on to aluminum (as hydroxide salt). The adjuvant system,
AS04, is composed of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) adsorbed
on to aluminum (as hydroxide salt).
CERVARIX is prepared by combining the adsorbed VLPs of each HPV type together with the AS04 adjuvant system in sodium chloride, sodium dihydrogen phosphate dihydrate, and Water for Injection.
CERVARIX is a sterile suspension for intramuscular injection. Each 0.5-mL dose
is formulated to contain 20 mcg of HPV type 16 L1 protein, 20 mcg of HPV type
18 L1 protein, 50 mcg of the 3-O-desacyl-4'-monophosphoryl lipid A (MPL),
and 0.5 mg of aluminum hydroxide. Each dose also contains 4.4 mg of sodium chloride
and 0.624 mg of sodium dihydrogen phosphate dihydrate. Each dose may also contain
residual amounts of insect cell and viral protein ( < 40 ng) and bacterial
cell protein ( < 150 ng) from the manufacturing process. CERVARIX does not
contain a preservative.
Last reviewed on RxList: 10/30/2009




Cervarix Drug Description
CERVARIX
[Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension
for Intramuscular Injection
DRUG DESCRIPTION
CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant]
is a non-infectious recombinant, AS04-adjuvanted vaccine that contains recombinant
L1 protein, the major antigenic protein of the capsid, of oncogenic HPV types
16 and 18. The L1 proteins are produced in separate bioreactors using the recombinant
Baculovirus expression vector system in a serum-free culture media composed
of chemically-defined lipids, vitamins, amino acids, and mineral salts. Following
replication of the L1 encoding recombinant Baculovirus in Trichoplusia ni
insect cells, the L1 protein accumulates in the cytoplasm of the cells. The
L1 proteins are released by cell disruption and purified by a series of chromatographic
and filtration methods. Assembly of the L1 proteins into virus-like particles
(VLPs) occurs at the end of the purification process. The purified, non-infectious
VLPs are then adsorbed on to aluminum (as hydroxide salt). The adjuvant system,
AS04, is composed of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) adsorbed
on to aluminum (as hydroxide salt).
CERVARIX is prepared by combining the adsorbed VLPs of each HPV type together with the AS04 adjuvant system in sodium chloride, sodium dihydrogen phosphate dihydrate, and Water for Injection.
CERVARIX is a sterile suspension for intramuscular injection. Each 0.5-mL dose
is formulated to contain 20 mcg of HPV type 16 L1 protein, 20 mcg of HPV type
18 L1 protein, 50 mcg of the 3-O-desacyl-4'-monophosphoryl lipid A (MPL),
and 0.5 mg of aluminum hydroxide. Each dose also contains 4.4 mg of sodium chloride
and 0.624 mg of sodium dihydrogen phosphate dihydrate. Each dose may also contain
residual amounts of insect cell and viral protein ( < 40 ng) and bacterial
cell protein ( < 150 ng) from the manufacturing process. CERVARIX does not
contain a preservative.
Last reviewed on RxList: 10/30/2009




Cervarix Drug Description
CERVARIX
[Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension
for Intramuscular Injection
DRUG DESCRIPTION
CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant]
is a non-infectious recombinant, AS04-adjuvanted vaccine that contains recombinant
L1 protein, the major antigenic protein of the capsid, of oncogenic HPV types
16 and 18. The L1 proteins are produced in separate bioreactors using the recombinant
Baculovirus expression vector system in a serum-free culture media composed
of chemically-defined lipids, vitamins, amino acids, and mineral salts. Following
replication of the L1 encoding recombinant Baculovirus in Trichoplusia ni
insect cells, the L1 protein accumulates in the cytoplasm of the cells. The
L1 proteins are released by cell disruption and purified by a series of chromatographic
and filtration methods. Assembly of the L1 proteins into virus-like particles
(VLPs) occurs at the end of the purification process. The purified, non-infectious
VLPs are then adsorbed on to aluminum (as hydroxide salt). The adjuvant system,
AS04, is composed of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) adsorbed
on to aluminum (as hydroxide salt).
CERVARIX is prepared by combining the adsorbed VLPs of each HPV type together with the AS04 adjuvant system in sodium chloride, sodium dihydrogen phosphate dihydrate, and Water for Injection.
CERVARIX is a sterile suspension for intramuscular injection. Each 0.5-mL dose
is formulated to contain 20 mcg of HPV type 16 L1 protein, 20 mcg of HPV type
18 L1 protein, 50 mcg of the 3-O-desacyl-4'-monophosphoryl lipid A (MPL),
and 0.5 mg of aluminum hydroxide. Each dose also contains 4.4 mg of sodium chloride
and 0.624 mg of sodium dihydrogen phosphate dihydrate. Each dose may also contain
residual amounts of insect cell and viral protein ( < 40 ng) and bacterial
cell protein ( < 150 ng) from the manufacturing process. CERVARIX does not
contain a preservative.
Last reviewed on RxList: 10/30/2009





Other reviews about Human Papillomavirus Bivalent Vaccine on wordpress

BT PHARMA successfully closes €1.3 million bridging round
  by pharmabiotechfrance
Bridging funds to move candidate therapeutic vaccine up to phase I / II clinical trials for treatment of patients suffering from high-grade lesions provoked by Human Papillomavirus. Toulouse, France — Monday, May […]


BT PHARMA appoints Martin Koch as Vice President Finance and Administration
  by pharmabiotechfrance
Professional in Biotech Finance brings top management and international experience to BT PHARMA &mdash forerunner in Therapeutic Vaccines Toulouse, France — Monday September 17, 2007. BT PHARMA S.A., forerunner in the development of […]


Human Papillomavirus Vaccination — Reasons for Caution
  by tasti
Human Papillomavirus Vaccination — Reasons for Caution Charlotte J. Haug, M.D., Ph.D. PDF Related Article by Kim, J. J. PubMed Citation Despite great expectations and promising results of clinical trials, we still lack […]


HPV: The Basics
  by annayeung213
Human papillomavirus (HPV) is a popular subject these days (in my world at least, I’m supposed to be working on my paper right now).  With the advent of […]


Second HPV Vaccine Backed for Girls, Women
  by Amber
  [caption id="attachment_20" align="aligncenter" width="300" caption="Atomic Model of Papillomavirus"][/caption]     The majority of a federal advisory panel agreed that the data on a recombinant bivalent human papillomavirus vaccine indicate that the […]


GlaxoSmithKline - Products
  by El Horror
About - Every second: Distributes more than 35 doses of vaccine. - Every minute: More than 1,100 prescriptions are written for GSK products. - Every hour: Spends more than $562,000 to […]


Merck - Business
  by El Horror
About - Merial = Merger of Merck & Co. Inc. (MSD AgVet) and Sanofi-Aventis (Rhone Mérieux) in 1997. In 2009 Merck sells its 50% to Sanofi-Aventis for $4 billion […]


FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP)
  by JOC
MMWR  May 28, 2010  V.59 N.20 p.626-629 On October 16, 2009, the Food and Drug Administration (FDA) licensed bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females […]


ACIP Recommendations on HPV vaccines: Males, Females
  by davidrcurry
The MMWR Weekly for May 28, 2010 / Vol. 59 / No. 20 / Pg. 613 - 648, includes: - FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) […]


Recommended Adult Immunization Schedule: United States, 2010 Advisory Committee on Immunization Practices
  by JOC
Ann Intern Med  5 January 2010 V.152 N.1 p.36-39 Clinical Guidelines From the Centers for Disease Control and Prevention, Atlanta, Georgia. The Advisory Committee on Immunization Practices (ACIP) annually reviews […]



Other reviews about Human Papillomavirus Bivalent Vaccine on web:

Bivalent Vaccine: Do you know the latest information on HPV, the most common sexually transmitted disease in the United States? Human Papillomavirus Disease and Vaccines: Bivalent Vaccine


Vaccines and Related Biological Products Advisory Committee (VRBPAC) Briefing Document September 9, 2009 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant


Human Papillomavirus Bivalent (Types 16, 18) Vaccine, Recombinant. Cervarix - Human Papillomavirus Vaccine


Physician reviewed human papillomavirus (HPV) vaccine, bivalent patient information - includes human papillomavirus (HPV) vaccine, bivalent description, dosage and directions. human papillomavirus (HPV) vaccine, bivalent medical facts from ...


Efficacy of a prophylactic adjuvanted bivalent L1 virus-like–particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a ... Assessing Human Papillomavirus Vaccine Efficacy and Safety ...


Centers for Disease Control and Prevention - Your Online Source for Credible Health Information FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2 ...


[Vaccine. 2006] Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control ... Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine


1. MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination ... FDA licensure of bivalent human papillomavirus vaccine (HPV2 ...


Learn about the prescription medication Cervarix (Human Papillomavirus Bivalent Vaccine), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling Cervarix (Human Papillomavirus Bivalent Vaccine) Drug Information ...


Drug Name: Cervarix [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant. Company: GlaxoSmithKline Approval Status: Approved October 2009 Newly Approved Drug Therapies (1070) Cervarix [Human ...





Featured Reviews

Reviews Theophylline in 5% Dextrose Injection Excel Container

Theophylline in 5% Dextrose Injection Excel Container Drug Description Theophylline in 5% Dextrose Injections USP Excel Container Do not admix with other drugs. DRUG DESCRIPTION Theophylline in 5% Dextrose Injections USP are sterile,...
Read More  |  Review This
Reviews Hepatitis A Inactivated & Hepatitis B

Twinrix Drug Description TWINRIX® [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine] DRUG DESCRIPTION What are the possible side effects of this vaccine (Twinrix)? You should not receive a booster vaccine if...
Read More  |  Review This
Reviews Drisdol

Drisdol Drug Description DRISDOL® (ergocalciferol, USP) 50,000 IU Capsule DRUG DESCRIPTION What are the possible side effects of ergocalciferol (Calciferol, Drisdol, Vitamin D)? Get emergency medical help if you have any of...
Read More  |  Review This
Reviews Namenda

Namenda Drug Description Namenda (memantine hydrochloride) Tablets/Oral Solution DRUG DESCRIPTION What are the possible side effects of memantine (Namenda)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Prolastin

Prolastin Drug Description Prolastin® Alpha1-Proteinase Inhibitor (Human) DRUG DESCRIPTION What are the possible side effects of alpha 1-proteinase inhibitor (Aralast, Aralast NP, Prolastin, Zemaira)? Get emergency medical help...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....